## Alberto Chiesa

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/565229/publications.pdf

Version: 2024-02-01

72 papers 6,895 citations

147801 31 h-index 71 g-index

74 all docs

74 docs citations

times ranked

74

7081 citing authors

#	Article	IF	CITATIONS
1	Mindfulness-Based Cognitive Therapy vs. Psycho-education for Patients with Anxiety Disorders Who Did Not Achieve Remission Following Adequate Pharmacological Treatment. Mindfulness, 2021, 12, 2059-2075.	2.8	1
2	Associations Between Mindfulness and Emotion Regulation: the Key Role of Describing and Nonreactivity. Mindfulness, 2019, 10, 366-375.	2.8	49
3	Citation patterns and trends of systematic reviews about mindfulness. Complementary Therapies in Clinical Practice, 2017, 28, 26-37.	1.7	29
4	Embodied Mindfulness. Mindfulness, 2017, 8, 1160-1171.	2.8	77
5	Effectiveness of traditional meditation retreats: A systematic review and meta-analysis. Journal of Psychosomatic Research, 2017, 92, 16-25.	2.6	82
6	Insomnia and Somnolence Associated With Second-Generation Antidepressants During the Treatment of Major Depression. Journal of Clinical Psychopharmacology, 2015, 35, 296-303.	1.4	44
7	Genetics of psychotropic medication induced side effects in two independent samples of bipolar patients. Journal of Neural Transmission, 2015, 122, 43-58.	2.8	14
8	Mindfulness-based cognitive therapy vs. psycho-education for patients with major depression who did not achieve remission following antidepressant treatment. Psychiatry Research, 2015, 226, 474-483.	3.3	54
9	Psychological Mechanisms of Mindfulness-Based Interventions. Holistic Nursing Practice, 2014, 28, 124-148.	0.7	88
10	Are Mindfulness-Based Interventions Effective for Substance Use Disorders? A Systematic Review of the Evidence. Substance Use and Misuse, 2014, 49, 492-512.	1.4	262
11	Disentangling the neural mechanisms involved in Hinduism- and Buddhism-related meditations. Brain and Cognition, 2014, 90, 32-40.	1.8	71
12	Lack of influence of rs4680 (COMT) and rs6276 (DRD2) on diagnosis and clinical outcomes in patients with major depression. International Journal of Psychiatry in Clinical Practice, 2014, 18, 97-102.	2.4	19
13	Family history of major depression and residual symptoms in responder and non-responder depressed patients. Comprehensive Psychiatry, 2014, 55, 51-55.	3.1	8
14	Epistatic Interactions between CREB and CREM Variants in Affective Disorder. Psychiatry Investigation, 2014, 11, 200.	1.6	2
15	The Difficulty of Defining Mindfulness: Current Thought and Critical Issues. Mindfulness, 2013, 4, 255-268.	2.8	212
16	Influence of family history of major depression, bipolar disorder, and suicide on clinical features in patients with major depression and bipolar disorder. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 93-103.	3.2	24
17	Case-control association study of 36 single-nucleotide polymorphisms within 10 candidate genes for major depression and bipolar disorder. Psychiatry Research, 2013, 209, 121-123.	3.3	22
18	Mindfulness: Top–down or bottom–up emotion regulation strategy?. Clinical Psychology Review, 2013, 33, 82-96.	11.4	328

#	Article	IF	CITATIONS
19	Investigation of Epistasis Between <i>DAOA</i> and <i>5HTR1A</i> Variants on Clinical Outcomes in Patients with Schizophrenia. Genetic Testing and Molecular Biomarkers, 2013, 17, 504-507.	0.7	8
20	Authors' reply to "Recommendations for conducting mindfulness based cognitive therapy trials― Psychiatry Research, 2013, 207, 232-233.	3.3	0
21	Social adjustment among treatment responder patients with mood disorders. Journal of Affective Disorders, 2013, 150, 961-966.	4.1	2
22	Side effects associated with psychotropic medications in patients with bipolar disorder: evidence from two independent samples. Journal of Psychopharmacology, 2013, 27, 616-628.	4.0	19
23	Investigation of possible epistatic interactions between <i>GRIA2</i> and <i>GRIA4</i> variants on clinical outcomes in patients with major depressive disorder. Journal of International Medical Research, 2013, 41, 809-815.	1.0	7
24	Newer antidepressants and panic disorder. International Clinical Psychopharmacology, 2013, 28, 33-45.	1.7	50
25	Quetiapine for bipolar depression. International Clinical Psychopharmacology, 2012, 27, 76-90.	1.7	40
26	Mindfulness-Based Cognitive Therapy Versus Psycho-Education for Patients with Major Depression Who Did Not Achieve Remission Following Antidepressant Treatment: A Preliminary Analysis. Journal of Alternative and Complementary Medicine, 2012, 18, 756-760.	2.1	49
27	Failure to Replicate Influence of GRIK4 and GNB3 Polymorphisms on Treatment Outcome in Major Depression. Neuropsychobiology, 2012, 65, 70-75.	1.9	22
28	Case–control association study of 14 variants of CREB1, CREBBP and CREM on diagnosis and treatment outcome in major depressive disorder and bipolar disorder. Psychiatry Research, 2012, 198, 39-46.	3.3	23
29	Case–control association study ofGRIA1,GRIA2andGRIA4polymorphisms in bipolar disorder. International Journal of Psychiatry in Clinical Practice, 2012, 16, 18-26.	2.4	8
30	DAOA Variants on Diagnosis and Response to Treatment in Patients with Major Depressive Disorder and Bipolar Disorder. Journal of International Medical Research, 2012, 40, 258-265.	1.0	5
31	Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to antipsychotic treatment in patients with schizophrenia. Neuroscience Letters, 2012, 506, 170-174.	2.1	15
32	Possible influence of CREB1, CREBBP and CREM variants on diagnosis and treatment outcome in patients with schizophrenia. Neuroscience Letters, 2012, 508, 37-41.	2.1	9
33	Influence of <i>BDNF</i> Variants on Diagnosis and Response to Treatment in Patients with Major Depression, Bipolar Disorder and Schizophrenia. Neuropsychobiology, 2012, 65, 1-11.	1.9	53
34	Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to treatment in patients with major depressive disorder. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 305-311.	3.2	30
35	Case–control association study for 10 genes in patients with schizophrenia: influence of 5HTR1A variation rs10042486 on schizophrenia and response to antipsychotics. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 199-205.	3.2	31
36	The challenge of uncovering the genetics of anxiety. Acta Psychiatrica Scandinavica, 2012, 125, 185-186.	4.5	3

3

#	Article	IF	CITATIONS
37	DAOAvariants and schizophrenia: Influence on diagnosis and treatment outcomes. International Journal of Psychiatry in Clinical Practice, 2011, 15, 303-310.	2.4	4
38	Mindfulness-Based Interventions for Chronic Pain: A Systematic Review of the Evidence. Journal of Alternative and Complementary Medicine, 2011, 17, 83-93.	2.1	281
39	Clinical and Demographic Predictors of Improvement during Duloxetine Treatment in Patients with Major Depression. Clinical Drug Investigation, 2011, 31, 385-405.	2.2	10
40	Novel Antidepressants and Panic Disorder: Evidence beyond Current Guidelines. Neuropsychobiology, 2011, 63, 1-7.	1.9	20
41	Does mindfulness training improve cognitive abilities? A systematic review of neuropsychological findings. Clinical Psychology Review, 2011, 31, 449-464.	11.4	946
42	COMT and age at onset in mood disorders: A replication and extension study. Neuroscience Letters, 2011, 498, 218-221.	2.1	32
43	Mindfulness based cognitive therapy for psychiatric disorders: A systematic review and meta-analysis. Psychiatry Research, 2011, 187, 441-453.	3.3	518
44	No influence of PTGS2 polymorphisms on response and remission to antidepressants in major depression. Psychiatry Research, 2011, 188, 166-169.	3.3	10
45	Influence of TPH2 variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia. Psychiatry Research, 2011, 189, 26-32.	3.3	42
46	A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. International Clinical Psychopharmacology, 2011, 26, 130-140.	1.7	148
47	Sexual Side Effects of Pharmacological Treatment of Psychiatric Diseases. Clinical Pharmacology and Therapeutics, 2011, 89, 142-147.	4.7	77
48	A preliminary investigation of the influence of CREB1 gene on treatment resistance in major depression. Journal of Affective Disorders, 2011, 128, 56-63.	4.1	45
49	Mindfulnessâ€based approaches: are they all the same?. Journal of Clinical Psychology, 2011, 67, 404-424.	1.9	311
50	Safety and Tolerability of Lamotrigine. Clinical Neuropharmacology, 2011, 34, 39-47.	0.7	53
51	Letter to the Editor: Response to  A systematic review of neurobiological and clinical features of mindfulness meditations'. Psychological Medicine, 2011, 41, 666-668.	4.5	1
52	Neuro-imaging of mindfulness meditations: implications for clinical practice. Epidemiology and Psychiatric Sciences, 2011, 20, 205-210.	3.9	17
53	Improving psychotherapy research: The example of mindfulness based interventions. World Journal of Methodology, 2011, 1, 4.	3.5	12
54	Correlation of a set of gene variants, life events and personality features on adult ADHD severity. Journal of Psychiatric Research, 2010, 44, 598-604.	3.1	25

#	Article	IF	Citations
55	Functional neural correlates of mindfulness meditations in comparison with psychotherapy, pharmacotherapy and placebo effect. Is there a link?. Acta Neuropsychiatrica, 2010, 22, 104-117.	2.1	36
56	No Influence of DTNBP1 Polymorphisms on the Response to Aripiprazole. Neuropsychobiology, 2010, 62, 245-249.	1.9	5
57	No influence of <i>SLC6A3 </i> 40 base VNTR polymorphism on the response to risperidone. International Journal of Psychiatry in Clinical Practice, 2010, 14, 228-232.	2.4	2
58	No influence of FAT polymorphisms in response to aripiprazole. Journal of Human Genetics, 2010, 55, 32-36.	2.3	6
59	A systematic review of neurobiological and clinical features of mindfulness meditations. Psychological Medicine, 2010, 40, 1239-1252.	4.5	533
60	Predictors of Early Worsening after Switch to Aripiprazole. Clinical Drug Investigation, 2010, 30, 187-193.	2.2	13
61	Influence of neuronal cell adhesion molecule (NCAM1) variants on suicidal behaviour and correlated traits. Psychiatry Research, 2010, 179, 222-225.	3.3	10
62	Influence of DAOA gene variants on antipsychotic response after switch to aripiprazole. Psychiatry Research, 2010, 178, 430-432.	3.3	9
63	Vipassana Meditation: Systematic Review of Current Evidence. Journal of Alternative and Complementary Medicine, 2010, 16, 37-46.	2.1	91
64	Clinical Roundup: How Do You Treat Insomnia in Your Practice?â€"Part 1. Alternative and Complementary Therapies, 2010, 16, 242-245.	0.1	1
65	Do the estrogen receptors 1 gene variants influence the temperament and character inventory scores in suicidal attempters and healthy subjects?. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2009, 150B, 434-438.	1.7	10
66	Influence of TAAR6 polymorphisms on response to aripiprazole. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 822-826.	4.8	9
67	Association between the estrogen receptor TA polymorphism and Harm avoidance. Neuroscience Letters, 2009, 467, 155-158.	2.1	16
68	Zen Meditation: An Integration of Current Evidence. Journal of Alternative and Complementary Medicine, 2009, 15, 585-592.	2.1	64
69	Immediate versus gradual suspension of previous treatments during switch to aripiprazole: Results of a randomized, open label study. European Neuropsychopharmacology, 2009, 19, 562-570.	0.7	49
70	Mindfulness-Based Stress Reduction for Stress Management in Healthy People: A Review and Meta-Analysis. Journal of Alternative and Complementary Medicine, 2009, 15, 593-600.	2.1	1,232
71	Treatment-Emergent Sexual Dysfunction Related to Antidepressants. Journal of Clinical Psychopharmacology, 2009, 29, 259-266.	1.4	455
72	Common genetic, clinical, demographic and psychosocial predictors of response to pharmacotherapy in mood and anxiety disorders. International Clinical Psychopharmacology, 2009, 24, 1-18.	1.7	42